Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population

International Journal of Cardiology

Volumn 133, Issue 3, 2009, Pages 346-353

  Marques Vidal, Pedro ^a,b   Rodondi, Nicolas ^c   Bochud, Murielle ^b   Chiolero, Arnaud ^b   Pécoud, Alain ^c   Hayoz, Daniel ^d   Paccaud, Fred ^b   Mooser, Vincent ^e   Firmann, Mathieu ^d   Waeber, Gérard ^d   Vollenweider, Peter ^d  

^a CardioMet   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Coronary heart disease; Epidemiology; Framingham risk function; Mortality; Primary prevention; Switzerland

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACCURACY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; CALIBRATION; COMPARATIVE STUDY; CORONARY DISEASE; CROSS-SECTIONAL STUDY; MIDDLE AGED; POPULATION GROUP; PREDICTIVE VALUE; RISK ASSESSMENT; SWITZERLAND;

ADULT; AGED; CALIBRATION; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POPULATION GROUPS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SWITZERLAND;

EID: 63149197756     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.01.004     Document Type: Article

References (47)

1. Mackay J., and Mensah G.A. Atlas of heart disease and stroke vol. 1 (2004), World Health Organization, Geneva, Switzerland
2. Mathers C.D., and Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3 (2006) e442
3. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., and Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15 (1994) 1300-1331
4. Wood D., De Backer G., Faergeman O., et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 16 (1998) 1407-1414
5. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. Br Med J 320 (2000) 659-661
6. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol In adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
7. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
8. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehab 10 (2003) S1-S10
9. Mosca L., Appel L.J., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 (2004) 672-693
10. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105 (2002) 310-315
11. Conroy R.M., Pyörälä K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24 (2003) 987-1003
12. Ridker P.M., Buring J.E., Rifai N., and Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 297 (2007) 611-619
13. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
14. Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353 (1999) 1547-1557
15. National Heart Lung and Blood Institute NIoH. Morbidity and mortality: 2004 chartbook on cardiovascular, lung, and blood diseases (2005), National Institutes of Health, Bethesda, USA
16. Harper S., Lynch J., Burris S., and Davey S.G. Trends in the black-white life expectancy gap in the United States, 1983-2003. JAMA 297 (2007) 1224-1232
17. D'Agostino Sr. R.B., Grundy S., Sullivan L.M., and Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286 (2001) 180-187
18. Marrugat J., D'Agostino R., Sullivan L., et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 57 (2003) 634-638
19. Liu J., Hong Y., D'Agostino Sr. R.B., et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 291 (2004) 2591-2599
20. Empana J.P., Ducimetière P., Arveiler D., et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 24 (2003) 1903-1911
21. Wallis E.J., Ramsay L.E., Ul Haq I., et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. Br Med J 320 (2000) 671-676
22. Menotti A., Puddu P.E., and Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 21 (2000) 365-370
23. Thomsen T.F., McGee D., Davidsen M., and Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 31 (2002) 817-822
24. Brindle P., Emberson J., Lampe F., et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. Br Med J 327 (2003) 1267
25. Hense H.W., Schulte H., Löwel H., Assmann G., and Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 24 (2003) 937-945
26. Getz L., Sigurdsson J.A., Hetlevik I., et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. Br Med J 331 (2005) 551
27. Eichler K., Puhan M.A., Steurer J., and Bachmann L.M. Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 153 (2007) 722-731 731
28. Marteau T.M., and Kinmonth A.L. Screening for cardiovascular risk: public health imperative or matter for individual informed choice?. Br Med J 325 (2002) 78-80
29. Hartz I., Njolstad I., and Eggen A.E. Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromso study 2001. Eur Heart J 26 (2005) 2673-2680
30. Verschuren W.M., Jacobs D.R., Bloemberg B.P., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274 (1995) 131-136
31. van den Hoogen P.C., Feskens E.J., Nagelkerke N.J., et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 342 (2000) 1-8
32. Levi F., Lucchini F., Negri E., and La V.C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 88 (2002) 119-124
33. Rodondi N., Cornuz J., Marques-Vidal P., et al. Aspirin use for the primary prevention of coronary heart disease: A population-based study in Switzerland. Prev Med (2007)
34. El Assaad M.A., Topouchian J.A., Darne B.M., and Asmar R.G. Validation of the Omron HEM-907 device for blood pressure measurement. Blood Press Monit 7 (2002) 237-241
35. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 153 (1993) 154-183
36. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269 (1993) 3015-3023
37. Rickenbach M., Wiestlisbach W., Barrazoni F., and Gutzwiller F. Hospitalisations pour infarctus du myocarde dans les cantons de Vaud, Fribourg et Tessin: résultats de l'étude MONICA pour la période 1985-1988. Médecine et Hygiène 50 (1992) 350-354
38. Fassa A.A., Urban P., Radovanovic D., et al. Trends in reperfusion therapy of ST segment elevation myocardial infarction in Switzerland: six year results from a nationwide registry. Heart 91 (2005) 882-888
39. Chambless L., Keil U., Dobson A., et al. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. Circulation 96 (1997) 3849-3859
40. Salomaa V., Ketonen M., Koukkunen H., et al. Decline in out-of-hospital coronary heart disease deaths has contributed the main part to the overall decline in coronary heart disease mortality rates among persons 35 to 64 years of age in Finland: the FINAMI study. Circulation 108 (2003) 691-696
41. Gerber Y., Jacobsen S.J., Frye R.L., et al. Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation 113 (2006) 2285-2292
42. Rothwell P.M., Coull A.J., Silver L.E., et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366 (2005) 1773-1783
43. Marrugat J., Elosua R., Aldasoro E., et al. Regional variability in population acute myocardial infarction cumulative incidence and mortality rates in Spain 1997 and 1998. Eur J Epidemiol 19 (2004) 831-839
44. Löwel H., Meisinger C., Heier M., and Hormann A. The population-based acute myocardial infarction (AMI) registry of the MONICA/KORA study region of Augsburg. Gesundheitswesen 67 Suppl 1 (2005) S31-S37
45. Panagiotakos D.B., Fitzgerald A.P., Pitsavos C., et al. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic J Cardiol 48 (2007) 55-63
46. Sans S., Fitzgerald A.P., Royo D., Conroy R., and Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España. Rev Esp Cardiol 60 (2007) 476-485
47. Lutz J.M., Pury P., Fioretta G., and Raymond L. The impact of coding process on observed cancer mortality trends in Switzerland. Eur J Cancer Prev 13 (2004) 77-81